Pulmonary multidrug codelivery of curcumin nanosuspensions and ciprofloxacin with N-acetylcysteine for lung infection therapy

Yanchao Liu,Yingying Ma,Linying Xue,Wenhao Guan,Yancai Wang
DOI: https://doi.org/10.1016/j.jddst.2023.104474
IF: 5
2023-06-01
Journal of Drug Delivery Science and Technology
Abstract:To better address the etiology of lung infections and the delivery limitations that exist, the development of a pulmonary inhalation formulation with antibacterial and mucolytic effects is necessary. This study was conducted using multidrug dry powder in one step to treat pulmonary infections. The optimal ratio of drugs for antibacterial activity was determined by the checkerboard method. The appearance of the dry powder for inhalation was yellow, and SEM images revealed that the powder was sphere-like, with a controlled particle size of 6 μm or less, good dispersion and a wrinkled and depressed surface. Confocal laser scanning microscopy (CLSM) images revealed that curcumin nanoparticles were uniformly distributed in the dry powder inhalation. Both the twin stage impinger (TSI) and Next Generation Impactor (NGI) showed that the multidrug powder has excellent aerosol performance, with a fine particle fraction (FPF) ranging from 68.93% to 77.75%. The multidrug powder presented satisfactory antibacterial effects at low doses, thereby reducing systemic toxicity due to high-dose delivery. In vitro drug release experiments also demonstrated that the powder had great release properties. In conclusion, a multidrug codelivery system of curcumin nanosuspensions and ciprofloxacin with N-acetylcysteine dry powder was prepared that was suitable for lung infection therapy.
pharmacology & pharmacy
What problem does this paper attempt to address?